Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
A snapshot of Obamacare enrollment in seven states suggests the law hasn’t significantly increased competition, but it has shuffled market share for some insurers, including Indianapolis-based WellPoint Inc.
Anthem Blue Cross and Blue Shield has signed a new kind of contract with the Franciscan Alliance hospital system that allows Franciscan to make more money only if it saves money for Anthem.
Obamacare opponents predicted early on that insurance co-ops created by the law would fail, but several are doing well by combining low premiums with a certain homespun appeal.
Nearly 65,000 Indiana residents have signed up for private insurance under the federal health care law, but the number is still far short of initial projections as the open enrollment deadline nears.
House Public Health Chairman Ed Clere said Tuesday that negotiators had found a compromise that would ban new construction for two years except in counties whose nursing homes are at 90-percent capacity or higher.
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
The extension was part of a major package of regulations that sets ground rules for 2015, the second year of government-subsidized health insurance markets under Obama's law — and the first year that larger employers will face a requirement to provide coverage.
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Health insurers such as Indianapolis-based WellPoint Inc. and Louisville-based Humana Inc. stand to receive $5.5 billion next year to cover losses from Obamacare in a program the law’s opponents label a bailout.
The bill passed 55-40 and now returns to the Indiana Senate, which has already passed the bill and can now approve changes made by the House or send the bill to a conference committee for further consideration.
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
Hospital company KentuckyOne Health, which employs more than 14,000 people in Kentucky and southern Indiana, says it has laid off about 500 people.
Community Achievement in Health Care Finalist
Pharmacists would be able to substitute an interchangeable biosimilar drug for a prescribed name-brand product under a bill passed by the Indiana House of Representatives on Tuesday.
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
